- Home
- CDXS
CDXS
Codexis Inc.
as 05-09-2025 11:33am EST
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Upcoming Earnings Alert:
Get ready for potential market movements as Codexis Inc. CDXS prepares to release earnings report on 14 May 2025.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 176.4M | IPO Year: | 2010 |
| Target Price: | $11.00 | AVG Volume (30 days): | 532.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $6.08 | Next Earning Date: | 05-14-2025 |
| Revenue: | $59,345,000 | Revenue Growth: | -15.39% |
| Revenue Growth (this year): | 12.62% | Revenue Growth (next year): | 22.11% |
Stock Insider Trading Activity of Codexis Inc. (CDXS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | CDXS | 10% Owner | Apr 30 '25 | Buy | $2.31 | 45,000 | $104,096.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Apr 25 '25 | Buy | $2.24 | 25,000 | $55,915.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Apr 15 '25 | Buy | $2.15 | 140,000 | $298,772.50 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Apr 8 '25 | Buy | $1.98 | 100,000 | $198,380.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Apr 1 '25 | Buy | $2.41 | 115,000 | $271,788.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 20 '25 | Buy | $2.54 | 92,923 | $236,266.02 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 13 '25 | Buy | $2.54 | 85,000 | $216,155.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 6 '25 | Buy | $2.61 | 100,000 | $261,350.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Mar 4 '25 | Buy | $2.67 | 65,000 | $172,273.00 | 9,655,000 | |
| Opaleye Management Inc. | CDXS | 10% Owner | Feb 28 '25 | Buy | $2.90 | 195,000 | $574,340.43 | 9,655,000 |
Latest Codexis Inc. News
CDXS Breaking Stock News: Dive into CDXS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
GlobeNewswire
9 days ago
Codexis to Report First Quarter 2025 Financial Results on May 14
Zacks
15 days ago
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
GlobeNewswire
a month ago
Codexis Announces Byron Dorgan to Retire from Board of Directors
Zacks
a month ago
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
GlobeNewswire
a month ago
Codexis Appoints Cynthia Collins to Board of Directors
MT Newswires
2 months ago
Codexis Signs First Contract for ECO Synthesis Manufacturing Services
GlobeNewswire
2 months ago
Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services
Compare CDXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXS Codexis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.